PE20200729A1 - Inhibidores de quinasa y usos de los mismos - Google Patents
Inhibidores de quinasa y usos de los mismosInfo
- Publication number
- PE20200729A1 PE20200729A1 PE2019002424A PE2019002424A PE20200729A1 PE 20200729 A1 PE20200729 A1 PE 20200729A1 PE 2019002424 A PE2019002424 A PE 2019002424A PE 2019002424 A PE2019002424 A PE 2019002424A PE 20200729 A1 PE20200729 A1 PE 20200729A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- independently
- kinase inhibitors
- alkyl
- protein kinase
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 abstract 1
- 206010051606 Necrotising colitis Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000001163 Tangier disease Diseases 0.000 abstract 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 abstract 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000009999 tuberous sclerosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507698P | 2017-05-17 | 2017-05-17 | |
| US201862664895P | 2018-04-30 | 2018-04-30 | |
| PCT/US2018/033266 WO2018213632A1 (en) | 2017-05-17 | 2018-05-17 | Kinase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200729A1 true PE20200729A1 (es) | 2020-07-23 |
Family
ID=64274744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002424A PE20200729A1 (es) | 2017-05-17 | 2018-05-17 | Inhibidores de quinasa y usos de los mismos |
| PE2024000411A PE20241932A1 (es) | 2017-05-17 | 2018-05-17 | Inhibidores de quinasa y usos de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000411A PE20241932A1 (es) | 2017-05-17 | 2018-05-17 | Inhibidores de quinasa y usos de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11203600B2 (https=) |
| EP (1) | EP3624797A4 (https=) |
| JP (2) | JP7064512B2 (https=) |
| KR (1) | KR102638151B1 (https=) |
| CN (3) | CN119285572A (https=) |
| AU (1) | AU2018269743B2 (https=) |
| BR (1) | BR112019023918A2 (https=) |
| CA (1) | CA3063934A1 (https=) |
| CL (1) | CL2019003263A1 (https=) |
| CO (1) | CO2019012957A2 (https=) |
| CR (1) | CR20190566A (https=) |
| DO (1) | DOP2019000290A (https=) |
| EC (1) | ECSP19089214A (https=) |
| IL (1) | IL270648B2 (https=) |
| MX (2) | MX2019013645A (https=) |
| MY (1) | MY200328A (https=) |
| PE (2) | PE20200729A1 (https=) |
| PH (1) | PH12019550235A1 (https=) |
| SG (1) | SG10201913927VA (https=) |
| TW (1) | TWI794232B (https=) |
| WO (1) | WO2018213632A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220072019A1 (en) * | 2018-10-19 | 2022-03-10 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| TWI873290B (zh) * | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2021187605A1 (ja) * | 2020-03-19 | 2021-09-23 | 田辺三菱製薬株式会社 | 含窒素複素環αシアノカルボニル化合物 |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| KR200493347Y1 (ko) | 2020-07-06 | 2021-03-17 | 박혜진 | 휴대가 용이한 마스크 |
| TW202302565A (zh) * | 2021-02-19 | 2023-01-16 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
| WO2022231927A1 (en) * | 2021-04-27 | 2022-11-03 | Merck Sharp & Dohme Llc | Phenyl azepines as ripk1 inhibitors and methods of use thereof |
| WO2022231928A1 (en) * | 2021-04-27 | 2022-11-03 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
| WO2023083847A1 (en) | 2021-11-11 | 2023-05-19 | Sanofi | Isoxazolidines as ripk1 inhibitors and use thereof |
| WO2024025817A1 (en) * | 2022-07-25 | 2024-02-01 | Denali Therapeutics Inc. | Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5- dihydro-2h-pyrido[3,4-f][l,4]oxazepine-9-carbonitrile |
| TW202412812A (zh) * | 2022-08-23 | 2024-04-01 | 美商建新公司 | 用於治療受體相互作用蛋白激酶１介導的疾病的方法 |
| WO2024158665A1 (en) * | 2023-01-23 | 2024-08-02 | Genzyme Corporation | Drug formulations of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido [3,4-f] [1,4] oxazepine-9-c arbonitrile |
| WO2025006575A1 (en) * | 2023-06-27 | 2025-01-02 | Genzyme Corporation | Process for preparing 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][l,4]oxazepine-9-carbonitrile |
| CN120365287A (zh) * | 2024-01-23 | 2025-07-25 | 南京天印健华医药科技有限公司 | 作为ripk1抑制剂的杂环化合物 |
| CN120365288A (zh) * | 2024-01-23 | 2025-07-25 | 南京天印健华医药科技有限公司 | 作为ripk1抑制剂的杂环化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3861187B2 (ja) * | 1996-08-02 | 2006-12-20 | 住友精化株式会社 | チアゼピン誘導体の製造方法 |
| CA2423902A1 (en) | 2000-09-27 | 2003-03-26 | Ajinomoto Co., Inc. | Benzodiazepine derivative |
| RU2456287C1 (ru) * | 2011-05-20 | 2012-07-20 | Николай Филиппович Савчук | Стимуляторы секреции инкретиновых гормонов, способы их получения и применения |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| CN104059068B (zh) | 2013-03-20 | 2017-02-08 | 中国科学院上海药物研究所 | β‑氨基羰基类化合物、其制备方法、药物组合物及其用途 |
| SG11201708622UA (en) * | 2015-02-02 | 2017-11-29 | Forma Therapeutics Inc | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| TWI730959B (zh) * | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| LT3307739T (lt) * | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
-
2018
- 2018-05-17 JP JP2019563596A patent/JP7064512B2/ja active Active
- 2018-05-17 SG SG10201913927VA patent/SG10201913927VA/en unknown
- 2018-05-17 CN CN202411240962.4A patent/CN119285572A/zh active Pending
- 2018-05-17 MX MX2019013645A patent/MX2019013645A/es unknown
- 2018-05-17 WO PCT/US2018/033266 patent/WO2018213632A1/en not_active Ceased
- 2018-05-17 EP EP18802127.3A patent/EP3624797A4/en active Pending
- 2018-05-17 CN CN201880047293.5A patent/CN110913858B/zh active Active
- 2018-05-17 AU AU2018269743A patent/AU2018269743B2/en active Active
- 2018-05-17 MY MYPI2019006664A patent/MY200328A/en unknown
- 2018-05-17 CN CN202411240964.3A patent/CN119264073A/zh active Pending
- 2018-05-17 KR KR1020197036911A patent/KR102638151B1/ko active Active
- 2018-05-17 IL IL270648A patent/IL270648B2/en unknown
- 2018-05-17 PE PE2019002424A patent/PE20200729A1/es unknown
- 2018-05-17 CR CR20190566A patent/CR20190566A/es unknown
- 2018-05-17 CA CA3063934A patent/CA3063934A1/en active Pending
- 2018-05-17 BR BR112019023918-9A patent/BR112019023918A2/pt not_active Application Discontinuation
- 2018-05-17 TW TW107116834A patent/TWI794232B/zh active
- 2018-05-17 PE PE2024000411A patent/PE20241932A1/es unknown
-
2019
- 2019-11-13 PH PH12019550235A patent/PH12019550235A1/en unknown
- 2019-11-14 MX MX2022010755A patent/MX2022010755A/es unknown
- 2019-11-14 DO DO2019000290A patent/DOP2019000290A/es unknown
- 2019-11-14 US US16/684,340 patent/US11203600B2/en active Active
- 2019-11-14 CL CL2019003263A patent/CL2019003263A1/es unknown
- 2019-11-19 CO CONC2019/0012957A patent/CO2019012957A2/es unknown
- 2019-12-16 EC ECSENADI201989214A patent/ECSP19089214A/es unknown
-
2021
- 2021-09-09 JP JP2021146775A patent/JP7241825B2/ja active Active
- 2021-10-26 US US17/511,193 patent/US12129263B2/en active Active
-
2024
- 2024-09-18 US US18/889,058 patent/US20250011338A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200729A1 (es) | Inhibidores de quinasa y usos de los mismos | |
| CO2019012998A2 (es) | Proteínas de unión a antígenos trem2 y usos de estas | |
| CL2017003007A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| ECSP14003642A (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| UY37594A (es) | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer | |
| MX2021008798A (es) | Receptores de antigeno quimerico que se dirigen al receptor acoplado a la proteina g y sus usos. | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX2017006448A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139). | |
| MX2015010935A (es) | Compuestos biciclicos antidiabeticos. | |
| PE20141178A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| CO6771450A2 (es) | Ureas asimétricas y usos médicos de las mismas | |
| MX2018015410A (es) | Esteres de oxaborol y sus usos. | |
| MX2019011225A (es) | Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al. | |
| MX2016012219A (es) | Agonistas de receptor fgf21 y usos del mismo. | |
| CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas | |
| CL2017001539A1 (es) | Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos | |
| MX2016010529A (es) | Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6). | |
| MX2019010941A (es) | Receptores de antigeno y usos de los mismos. | |
| CO2020000617A2 (es) | Novedosos compuestos que activan la ruta nrf2 | |
| PE20190104A1 (es) | Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos |